Want to see ANEB full AI Analyst Report?
ANEB Stock Chart & Stats
$0.32
$0.00(0.00%)
At close: 4:00 PM EDT
$0.32
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$0.01 - $2.85
Previous CloseN/A
Volume103.00
Average Volume (3M)291.00
Market Cap
$15.91M
Enterprise Value$32.45
Total Cash (Recent Filing)$9.04M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.11
Next Earnings
Sep 23, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.19
Shares Outstanding40,784,733
10 Day Avg. Volume71
30 Day Avg. Volume291
Financial Highlights & Ratios
PEG Ratio0.26
Price to Book (P/B)4.18
Price to Sales (P/S)0.00
P/FCF Ratio-7.67
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.46
Revenue Forecast (FY)$27.31M
Bulls Say, Bears Say
Bulls Say
Corporate StrategyBoard approves plan to go private at a 91% premium to previous close.
Bears Say
Stock PriceThe upside potential is limited as the shares approach the transaction price and exceed the 12-month price target.
Stock RatingStock rating downgraded to Hold.
Anebulo Pharmaceuticals News
ANEB FAQ
What was Anebulo Pharmaceuticals’s price range in the past 12 months?
Anebulo Pharmaceuticals lowest stock price was $0.01 and its highest was $2.85 in the past 12 months.
What is Anebulo Pharmaceuticals’s market cap?
Anebulo Pharmaceuticals’s market cap is $15.91M.
When is Anebulo Pharmaceuticals’s upcoming earnings report date?
Anebulo Pharmaceuticals’s upcoming earnings report date is Sep 23, 2026 which is in 18 days.
How were Anebulo Pharmaceuticals’s earnings last quarter?
Anebulo Pharmaceuticals released its earnings results on Feb 12, 2026. The company reported -$0.05 earnings per share for the quarter.
Is Anebulo Pharmaceuticals overvalued?
According to Wall Street analysts Anebulo Pharmaceuticals’s price is currently Overvalued.
Does Anebulo Pharmaceuticals pay dividends?
Anebulo Pharmaceuticals does not currently pay dividends.
What is Anebulo Pharmaceuticals’s EPS estimate?
Anebulo Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Anebulo Pharmaceuticals have?
Anebulo Pharmaceuticals has 40,784,733 shares outstanding.
What happened to Anebulo Pharmaceuticals’s price movement after its last earnings report?
Anebulo Pharmaceuticals reported an EPS of -$0.05 in its last earnings report. Following the earnings report the stock price went up 8.225%.
Which hedge fund is a major shareholder of Anebulo Pharmaceuticals?
Currently, no hedge funds are holding shares in ANEB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Anebulo Pharmaceuticals
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the United States. The company’s lead product candidate is the selonabant, a small-molecule antagonist of cannabinoid binding receptor type-1(CB1), which is in a phase II clinical trial to address the unmet medical need for a specific antidote for cannabis toxicity. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Lakeway, Texas.
Technical Analysis
Palatin Technologies
―
Tempest Therapeutics
―
Phio Pharmaceuticals
―
KALA BIO
―
Citius Pharmaceuticals
―
Ownership Overview
―
Insiders
0.30% Mutual Funds
51.73% Other Institutional Investors
47.97% Public Companies and
Individual Investors